RNA Interference Drug Pipeline Market Research Report 2022: Insights About 20+ Companies and 20+ Pipeline Drugs in the Pipeline Landscape – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “RNA interference – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “RNA interference – Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in RNA interference pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

RNA interference Emerging Drugs Chapters

This segment of the RNA interference report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

RNA interference Emerging Drugs

Fitusiran: Alnylam Pharmaceuticals

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by our collaborators at Sanofi Genzyme. The drug is currently in phase 3 of development for the treatment of patients with Haemophilia.

WVE 120102: WaVe life Sciences

WVE 120102 is being developed by WaVe life Sciences for the treatment of Huntington disease. The therapy is based on RNAi technology and targets a specific single nucleotide polymorphism (SNP3) within the huntingtin gene. It is currently in phase I/II of clinical development.

RNA interference: Therapeutic Assessment

This segment of the report provides insights about the different RNA interference drugs segregated based on following parameters that define the scope of the report.

Major Players working on RNA interference

There are approx. 20+ key companies which are developing the RNA interference. The companies which have their RNA interference drug candidates in the most advanced stage, i.e. phase 3 include, Alnylam Pharmaceuticals.

RNA interference: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses RNA interference therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging RNA interference drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence RNA interference R&D. The therapies under development are focused on novel approaches for RNA interference.

Current Scenario and Emerging Therapies:

• How many companies are developing RNA interference drugs?
• How many RNA interference drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for RNA interference?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the RNA interference therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for RNA interference and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Alnylam Pharmaceuticals
• WaVe life Sciences
• Medesis Pharma
• Bio-Path Holdings
• Sirnaomics
• Arrowhead Pharmaceuticals
• Silence Therapeutics
• Dicerna Pharmaceuticals
• Novo Nordisk
• Eli Lilly and Company
• Ionis Pharmaceuticals
• Quark Pharmaceuticals
• ProQR Therapeutics
• Arbutus Biopharma
• Atugen AG
• Sylentis
• Bristol-Myers Squibb
• OliX Pharmaceuticals
• Janssen Pharmaceuticals
• Amgen
• miRagen Therapeutics
• Regulus Therapeutics

Key Products

• Fitusiran
• WVE 120102
• siRNA therapeutic
• BP 1003
• STP 705

Research Programme: Short interfering RNA-based therapeutics

• IONIS AGT LRx
• QPI 1007
• Teprasiran
• Eluforsen
• RG 6346
• AB 729
• QR-421a
• Sepofarsen
• PF 4523655
• ALN VSP
• Atu027
• Bamosiran
• BMS 986263
• ARO APOC3
• Tivanisiran
• OLX 101A
• TAK 999
• Nedosiran
• Olpasiran
• Remlarsen
• MRG 110
• Lademirsen

Key Topics Covered:

Introduction

Executive Summary

RNA interference: Overview

• Structure
• Mechanism of Action

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

RNA interference – Analytical Perspective

In-depth Commercial Assessment

• RNA interference companies’ collaborations, Licensing, Acquisition – Deal Value Trends

RNA interference Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Fitusiran: Alnylam Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

IONIS AGT LRx: Ionis Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I/II)

• Comparative Analysis

QR-421a: ProQR Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Pre-clinical and Discovery Stage Products

• Comparative Analysis

BP 1003: Bio-Path Holdings

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

RNA interference Key Companies

RNA interference Key Products

RNA interference- Unmet Needs

RNA interference- Market Drivers and Barriers

RNA interference- Future Perspectives and Conclusion

RNA interference Analyst Views

RNA interference Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/d6wtm6.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900